Immune response to racotumomab in a child with relapsed neuroblastoma

Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampor, C., Guthmann, M. D., Scursoni, A., Cacciavillano, W., Torbidoni, A., Galluzzo, L., Camarero, S., Lopez, J., de Dávila, M. T. G., Fainboim, L., Chantada, G. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2012
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526767/
https://www.ncbi.nlm.nih.gov/pubmed/23267436
http://dx.doi.org/10.3389/fonc.2012.00195
Descripción
Sumario:Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.

Ejemplares similares